Table 1.
Clinicopathological and epidemiological characteristics of patients.
| Characteristic | Total (n = 148) | AC (n = 24) | TC (n = 18) | LCNEC (n = 57) | SCLC (n = 49) | P-value |
|---|---|---|---|---|---|---|
| Age, years | <.0001 | |||||
| Median[Q1, Q3] | 59[51.5-65] | 52[47.5, 63.5] | 50[41.25, 53] | 62[56, 67] | 60[54, 65.5] | |
| Gender, no. (%) | <.00001 | |||||
| Female | 26(17.6%) | 10(41.7%) | 8(44.4%) | 2(3.5%) | 6(12.2%) | |
| Male | 122(82.4%) | 14(58.3%) | 10(55.6%) | 55(96.5%) | 43(87.8%) | |
| Smoking, no. (%) | <.001 | |||||
| No | 34(23%) | 9(37.5%) | 11(61.1%) | 7(12.3%) | 7(14.3%) | |
| Yes | 102(68.9%) | 14(58.3%) | 6(33.3%) | 43(75.4%) | 39(79.6%) | |
| NA | 12(8.1%) | 1(4.2%) | 1(5.6%) | 7(12.3%) | 3(6.1%) | |
| Stage, no. (%) | <.0001 | |||||
| I | 31(20.9%) | 8(33.3%) | 11(61.1%) | 7(12.3%) | 5(10.2%) | |
| II | 12(8.1%) | 2(8.3%) | 1(5.6%) | 6(10.5%) | 3(6.1%) | |
| III | 32(21.6%) | 4(16.7%) | 1(5.6%) | 15(26.3%) | 12(24.5%) | |
| IV | 57(38.5%) | 8(33.3%) | 0(0%) | 27(47.4%) | 22(44.9%) | |
| NA | 16(10.8%) | 2(8.3%) | 5(27.8%) | 2(3.5%) | 7(14.3%) | |
| Treatment, no. (%) | <.00001 | |||||
| Systemic | 79(53.4%) | 9(37.5%) | 0(0%) | 36(63.2%) | 34(69.4%) | |
| Surgery | 69(46.6%) | 15(62.5%) | 18(100%) | 21(36.8%) | 15(30.6%) | |
| a Best response, no. (%) | <.01 | |||||
| PD | 2(2.5%) | 1(11.1%) | — | 0(0%) | 1(2.9%) | |
| PR | 37(46.8%) | 2(22.2%) | — | 13(36.1%) | 22(64.7%) | |
| SD | 13(16.5%) | 3(33.3%) | — | 5(13.9%) | 5(14.7%) | |
| NA | 27(34.2%) | 3(33.3%) | — | 18(50.0%) | 6(17.6%) | |
| Systemic regimen, no. (%) | <.001 | |||||
| EP | 34(43%) | 4(44.4%) | — | 10(27.8%) | 20(58.8%) | |
| EC | 11(13.9%) | 1(11.1%) | — | 2(5.6%) | 8(23.5%) | |
| IO | 2(2.5%) | 0(0%) | — | 2(5.6%) | 0(0%) | |
| EGFR-TKI | 2(2.5%) | 0(0%) | — | 2(5.6%) | 0(0%) | |
| Other chemotherapy | 11(13.9%) | 2(22.2%) | — | 8(22.2%) | 1(2.9%) | |
| NA | 19(24.1%) | 2(22.2%) | — | 12(33.3%) | 5(14.7%) | |
TC: typical carcinoid; AC: atypical carcinoid; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; EP: etoposide + cisplatin; EC: etoposide+ carboplatin; IO: immunotherapy;
Best response evaluated upon systemic treatment for unresectable tumors.